Recursion Pharmaceuticals

Contributing Author

Recent Articles by Recursion Pharmaceuticals

15 hours	Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update RXRX GlobeNewswire
15 hours	Recursion Announces CEO Transition Plan to Drive Next Phase of Growth RXRX GlobeNewswire
Nov-04	Recursion to Participate in Upcoming Investor Conferences RXRX GlobeNewswire
Oct-28	Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th RXRX GlobeNewswire
Aug-27	Recursion to Participate in Upcoming Investor Conferences RXRX GlobeNewswire
Aug-05	Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update RXRX GlobeNewswire
Jul-29	Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th RXRX GlobeNewswire
Jul-08	Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia RXRX GlobeNewswire
Jun-06	MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy RXRX GlobeNewswire
May-30	Recursion to Participate in Upcoming Investor Conferences RXRX GlobeNewswire
May-06	Recursion to Participate in Upcoming Investor Conferences RXRX GlobeNewswire
May-05	Recursion Reports First Quarter 2025 Financial Results and Provides Business Update RXRX GlobeNewswire